Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.23.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Operating Activities:    
Net loss $ (17,231) $ (18,041)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 4] 113 116
Stock-based compensation [note 8[c], note 8[e], note 8[f] and note 8[g]] 2,275 1,663
Shares issued as settlement with trade vendor   26
Accrued interest on SVB convertible debt [note 7] 606 560
Accretion of discount on modification of debt 107  
Changes in operating assets and liabilities:    
Grant receivable [note 3] (245) (160)
Prepaid expenses and other assets 1,517 (99)
Accounts payable (1,299) (185)
Accrued liabilities other 369 145
Accrued clinical liabilities (689) 1,694
Accrued compensation (444) (837)
Lease obligation [note 9] (58) (1)
Net cash used in operating activities (14,979) (15,119)
Financing Activities:    
Proceeds from exercise of warrants 227 24
Proceeds from ATM, net of issuance costs   1,499
Financing costs relating to November 2022 private placement (30)  
Taxes paid related to net share settlement of equity awards (220) (47)
Proceeds from May 2023 private placement, net of issuance costs 15,301  
Net cash provided by financing activities 15,278 1,476
Effect of exchange rate changes on cash 1 (1)
Net increase (decrease) in cash, cash equivalents and restricted cash 300 (13,644)
Cash, cash equivalents and restricted cash at beginning of the period 24,821 43,072
Cash, cash equivalents and restricted cash at end of the period $ 25,121 $ 29,428